Mufg Securities Americas Inc. Boosts Holdings in Boston Scientific Corporation $BSX

Mufg Securities Americas Inc. increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 21.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,957 shares of the medical equipment provider’s stock after acquiring an additional 7,168 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Boston Scientific were worth $3,901,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Baldwin Investment Management LLC grew its holdings in shares of Boston Scientific by 5.4% during the third quarter. Baldwin Investment Management LLC now owns 13,145 shares of the medical equipment provider’s stock worth $1,283,000 after purchasing an additional 675 shares during the last quarter. AXQ Capital LP purchased a new position in Boston Scientific during the 3rd quarter worth approximately $1,434,000. Compound Planning Inc. increased its position in Boston Scientific by 22.1% during the third quarter. Compound Planning Inc. now owns 13,445 shares of the medical equipment provider’s stock worth $1,313,000 after buying an additional 2,436 shares during the period. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after acquiring an additional 103 shares during the period. Finally, Fortis Capital Management LLC purchased a new position in shares of Boston Scientific during the third quarter worth approximately $5,895,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Citigroup reduced their price target on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Canaccord Genuity Group reduced their target price on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Wells Fargo & Company dropped their price target on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Truist Financial lowered their target price on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $74.37 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock’s 50 day moving average is $88.87 and its two-hundred day moving average is $96.32. Boston Scientific Corporation has a twelve month low of $72.69 and a twelve month high of $109.50. The firm has a market capitalization of $110.36 billion, a PE ratio of 38.33, a P/E/G ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.